Beverly Davidson Advances Gene Therapy for Huntington's Disease with Novel AAVs
Beverly Davidson, PhD, a geneticist and chief scientific strategy officer at the Children's Hospital of Philadelphia, has been recognized with the 2026 Outstanding Achievement Award by the American Society of Gene and Cell Therapy (ASGCT). Davidson's work focuses on developing novel adeno-associated viruses (AAVs) to target central nervous system disorders, particularly Huntington's disease (HD). Her research, conducted at Latus Bio, a biotech company she co-founded, aims to improve the delivery and potency of gene therapies for HD. Davidson's team has engineered AAVs to better target neuronal cells, overcoming challenges such as scalability and high peripheral exposure. The research includes the development of AAV-DB-3, a capsid that shows promise in targeting deep brain regions crucial for HD treatment. 
